USC BMT Program Achieves Overperforming Status Honor

The USC Blood and Marrow Transplant and Cell Therapy Program receives the highest possible score from the Center for International Blood and Marrow Transplant Research

The USC Blood and Marrow Transplant and Cell Therapy Program (USC BMT) recently achieved a +1 score from the Center for International Blood and Marrow Transplant Research (CIBMTR), a designation reflecting its exceptional one-year survival rate that exceeds predicted outcomes among transplant centers in the U.S. 

The USC BMT Program is one of just eight centers this year to have achieved this score —the highest possible from CIBMTR — with 176 centers included in its 2025 analysis. The USC BMT Program is also one of four programs to have achieved this status for the sixth consecutive year. 

In its yearly report, CIBMTR analyzes one-year allogeneic (donor transplants) survival rates from each transplant center in the United States, gathering data from three consecutive years of allogeneic recipients who have survived  their first year after transplant. The survival at each center is compared against others around the country, and each center is scored either a -1, 0 or +1 to indicate its performance. 

 With a one-year survival rate of 86%, USC BMT has one of the highest in the nation among adultallogeneic transplant centers.

 To learn more about the USC BMT program, click here.

Topics